© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Telehealth May Represent Up to 30% of US Medical Visits by 2026
May 27, 2025
Telemedicine's trajectory depends far more on future regulatory action than on health care's readiness or patient desire, according to a new report.
Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study
May 27, 2025
Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.
Combined Oral Contraceptive Use May Triple the Risk of Cryptogenic Stroke in Young Women
May 23, 2025
ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.
Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype
May 23, 2025
Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.
The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care
May 22, 2025
At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.
Roflumilast Topical Foam 0.3% Approved to Treat Plaque Psoriasis in People Aged 12 Years and Older
May 22, 2025
Itch relief in clinical trials was rapid with the nonsteroidal foam; it is applied once daily with no limitations on body area or duration of use.
Novel CBD Cream Shows Promise in Protecting Skin from UV-A Damage in First-Ever In-Human Trial
May 22, 2025
Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.
Moderna Announces Withdrawal of BLA for Flu/COVID-19 Combination Vaccine
May 22, 2025
Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.
Half of Adults with Severe Asthma Treated with Tezepelumab Discontinue OCS Use at 52 Weeks: Phase 3b WAYFINDER Trial
May 22, 2025
The WAYFINDER trial is the first to demonstrate the positive impact of the thymic stromal lymphopoietin antagonist on steroid-dependent severe asthma.
From Screening to Support: How PCPs Can Tackle PPD
May 21, 2025
ACOG 2025: Joy Baker, MD, urged primary care clinicians to screen early, refer confidently, and help change the statistics on maternal mental health.